The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Expert Highlights Potential of Immunotherapy in Gastric Cancer
August 29th 2016Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.
Expert Discusses Optimal Care for Relapsed/Refractory CLL
August 29th 2016Jennifer Woyach, MD, discussed using the FDA-approved agents ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta) in a hypothetical patient scenario, and highlighted emerging targets and treatments in relapsed/refractory chronic lymphocytic leukemia.
Study Calls for Interventions to Increase Colorectal Cancer Screening in Hispanic Men
August 28th 2016Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for one group—Hispanic men—rates have remained essentially unchanged, and a new study suggests that lower rates of screening may be the chief driver of this disparity.
Accurate Risk Status Assessment Critical to Prostate Cancer Care
August 25th 2016Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.
Expert Says Nivolumab Poised to Change Standard of Care in SCCHN
August 23rd 2016Robert L. Ferris, MD, PhD, discusses the findings of the CheckMate-141 study, potential biomarkers for nivolumab (Opdivo), and questions that remain regarding the use of the immunotherapy in squamous cell carcinoma of the head and neck.
EMA Initiates Official Regulatory Review of Neratinib in HER2+ Breast Cancer
August 23rd 2016The European Medicines Agency has validated the marketing authorization application for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.
Pembrolizumab to Have Critical Role in Head and Neck Cancer Treatment
August 21st 2016Joshua M. Bauml, MD, discusses the impact of pembrolizumab's (Keytruda's) success in recurrent or metastatic head and neck squamous cell carcinoma, the results of the KEYNOTE-055 study, and what he sees on the horizon for the PD-1 inhibitor in this field.
FDA Approval Sought for Daratumumab Combos in Multiple Myeloma
August 18th 2016A supplemental biologics license application has been submitted to the FDA for the use of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.
Venetoclax Shows Single-Agent Activity in AML
August 16th 2016Treatment with single-agent BCL-2 inhibitor venetoclax demonstrated an overall response rate of 19% with a tolerable safety profile in patients who were unfit for intensive chemotherapy for those with relapsed/refractory acute myeloid leukemia.